A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Phase 1 Completed 53 enrolled CureVac

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The primary objective of this clinical study is to assess the safety, and reactogenicity of CV7202 mRNA-rabies vaccine in healthy adults. Immunogenicity is also assessed.

Timeline

Start: 2018-10-12
Primary completion: 2021-11-23
Completion: 2021-11-23

Publications

Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, Walz L, Leroux-Roels G, von Sonnenburg F, Oostvogels L. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine. 2021 Feb 22;39(8):1310-1318. doi: 10.1016/j.vaccine.2020.12.070. Epub 2021 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CV7202	Messenger RNA (mRNA)	1 ug	Intramuscular
Subject	CV7202	Messenger RNA (mRNA)	2 ug	Intramuscular
Subject	CV7202	Messenger RNA (mRNA)	5 ug	Intramuscular
Comparator	Rabies vaccine	Vaccine	—	Intramuscular

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Summary

Timeline

Publications

Drugs

Indications